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Background. Adult-Onset Still’s Disease (AOSD) is an immune-mediated systemic disease with quotidian-spiking fever, rash, and
inﬂammatory arthritis. Hyperferritinemia is a prominent feature, often used for screening. Methods. The key terms “ferritin”
and “hyperferritinemia” were used to search PubMed and Medline and were cross-referenced with “Still’s Disease.” Results.
Hyperferritinemia, although nonspeciﬁc, is particularly prevalent in AOSD. While most clinicians associate ferritin with iron
metabolism,thisismostlytruefortheHisoformandnotfortheLisoformthattendstoincreasedramaticallyinhyperferritenemia.
Inthesesituations,hyperferritinemia isnotassociatedwithiron metabolism and may even mask an underlying iron deﬁciency. We
review, in systematic fashion, the current basic science and clinical literature regarding the regulation of ferritin and its use in the
diagnosis and management of AOSD. Conclusion. Serum hyperferritinemia in AOSD has been described for 2 decades, although
its mechanism has not yet been completely elucidated. Regulation by proinﬂammatory cytokines such as interleukin (IL)-1b, IL-6,
IL-18, MCSF, and INF-α provides a link to the disease pathogenesis and may explain rapid resolution of hyperferritinemia after
targeted treatment and inhibition of key cytokines.
1.Introduction
Adult-Onset Still’s disease (AOSD) is a rare, immune-medi-
ated, multisystem inﬂammatory disorder characterized by
quotidian spiking fevers, evanescent rash, and arthritis. It
is frequently underdiagnosed and one of the main reasons
for hospital admissions due to pyrexia of unknown origin
(PUO).
The disease characteristically aﬀects young individuals,
with three quarters of the patients reporting disease onset
between 16 and 35 years of age [1, 2]. Other symptoms
include myalgia, inﬂammatory myopathy, liver abnormali-
ties, pseudoangiocholitis, pleuritis, pericarditis, splenomega-
ly,pericardial tamponade andmyocarditis, pulmonaryﬁbro-
sis, pleural eﬀusions, adult respiratory distress syndrome,
interstitial nephritis, subacute glomerulitis, renal amyloi-
dosis, collapsing glomerulopathy, thrombotic thrombocy-
topenic purpura, pure red cell aplasia, cranial nerve palsies,
seizures, aseptic meningoencephalitis, and Miller-Fisher syn-
drome.
This syndrome was formerly thought to occur solely
in children as systemic-onset juvenile idiopathic arthritis
(SoJIA),previouslyknownasjuvenileStill’sdisease.Bywaters
described in, 1971, a new disease entity that he named adult
Still’s disease; it involved adult patients who did not meet the
criteria for classic rheumatoid arthritis (RA) but displayed
features similar to those described in pediatric Still’s disease
[3].
Its etiology remains unknown. An infectious etiology has
been postulated, although a deﬁnitive agent has never been
identiﬁed and infectious agents are thought to be innate
immunity triggers, leading to the clinical phenotype.
2. Methods
The key terms “ferritin” and “hyperferritinemia” were used
tosearchMedlineandPubmedandcross-referencedwiththe
key term “Still’s disease” and “Adult-Onset Still’s Disease” for
all available full-text articles. Studies identiﬁed by the search2 International Journal of Inﬂammation
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strategies were assessed for relevance prior to inclusion in
the paper. While the emphasis was on human studies, a
few selected animal studies were included which provided
important clues about the underlying pathophysiology.
3. Results
3.1. Regulation of Ferritin. A well-known feature of AOSD
has increased levels of serum ferritin, usually ﬁve times, or
more, above the upper limits of normal that at times may
be extreme (>50,000ug/dL). While by no means speciﬁc for
the disease, serum hyperferritinemia is often used to aid the
diagnosis of AOSD and serial serum levels are often used
as a sort of biomarker to monitor response to treatment.
Ferritin (apoferritin/iron-free ferritin) is a high-molecular-
weight protein (450 to 600kDa) composed of a nanocage of
24assembledsubunits.Itcansequesterupto4500ironatoms
[24]. It is 8–12nm in diameter which is as small as spherical
viruses [25, 26]. It is found in many tissues and cell types.
It is a necessary molecule for the cell’s respiratory function
where iron storage could cause free radical injury. The
best-known function of ferritin is storage of iron. Ferritin
captures the intracellular labile iron pool and thus “buﬀers”
itseﬀect.Itisalsoanacutephasereactant,involvedininﬂam-
matory processes, which includes oxidative-stress-induced
cell processes. Complementary DNA (antioxidant responsive
element/Maf recognition element) along with mRNA (iron
responsive element) regulates rate of ferritin synthesis [5,
27]. The cytoplasmic ferritin content is regulated by the
translation of ferritin mRNAs in response to an intracellular
pool of “chelatable” and “labile” iron. Inﬂammation is
associated with increased production of ferritin by the
histiocytomacrophage system and/or increased release from
damaged hepatocytes. However, the precise mechanism and
the regulation of this phenomenon are poorly deﬁned [28].
Ferritin levels are increased in a few autoimmune diseases
l i k eR Ab u tt h e yh a r d l ye v e rg oa sh i g ha si nA O S D[ 5].
3.2. Heme Oxygenase-1 Enzyme and Ferritin Expression.
There has been a close association between the heme oxy-
genase-1 (HO-1) enzyme and ferritin expression in AOSD.
HO-1 is an enzyme that degrades heme when induced to
CO, Fe2+, and biliverdin. It is expressed by macrophages
and endothelial cells in response to stress. Studies have
shown that HO-1 mRNA increases in AOSD and that it may
correlate with AOSD disease activity [15, 33], making it a
potentially useful biomarker.
3.3. Ferritin Isoforms. Isoelectric-focusing studies have iden-
tiﬁed several isoforms of ferritin. The acid form (H, heavy)
is found chieﬂy in organs with low iron content, such
as the heart and pancreas. In contrast, the base form (L,
light) is found in organs (liver, spleen) and the histiocyte-
macrophage system that has a signiﬁcant iron storage
capacity (Figure 1). The L-ferritin isoform is the one which
is released in the circulation. The H-isoform has multiple
catalytic sites and is faster than the L form. H-ferritin plays a
major role rapid detoxiﬁcation of iron and intracellular iron
transport, whereas L-ferritin is involved in iron nucleation,
mineralization, and long-term storage. The H:L ratio is
normally constant in a cell, although it may change in
hemochromatosis and other iron overload diseases [10–12].
T h eH:Lf e r r i t i nr a t i oh a sn o ty e tb e e nd e ﬁ n e di nA O S D .I n
situationsofironoverload,itmaybeadvantageoustothecell
to synthesize L-ferritin, since these ferritins are not only able
to store higher iron amounts but can also retain iron more
ﬁrmly and turn over iron more slowly than their H-ferritin
counterparts [11]. In diseases like hyperferritinemia cataract
syndrome, mutations in L ferritin have been documented
[50]. However, no such study in AOSD has been contacted
yet. A new isoform of ferritin has recently been described
in breast cancer patients, HIV patients, and in pregnancy
[51]. This ﬁnding suggests that there may be other isoforms
that have not been identiﬁed yet and could explain the
hyperferritinemia phenomenon in AOSD.
3.4. Ferritin and Disease Pathogenesis. The pathogenesis
behind increased ferritin levels is thought to be cytokine
mediated. Cytokines regulate ferritin synthesis at transcrip-
tional, posttranscriptional, and translational stages. Cy-
tokines implicated are IL1α,I L 1 β, IL18, tumor necrosis
factor-α (TNF-α), interferon-γ (IFN-γ), macrophage-colony
stimulating factor (M-CSF), IL6, and IL-18 [28, 52–55].
IL1α,IFN-γ,andTNF-αhaveshowntoinducetheexpression
ofH-ferritin[54,56,57].Translationofferritinisinducedby
IL1β,IL-6,orTNF-α[58].IL1βalsoaﬀectsferritinregulation
at a posttranscriptional stage [59]. The serum levels of Th1
cytokines and soluble IL-2 receptors are higher in AOSD
than in other inﬂammatory joint diseases and have been
correlated to the serum ferritin level [10].International Journal of Inﬂammation 3
Table 1: Diseases in which ferritin levels increase or decrease.
Ferritin levels increase Ferritin levels decrease
Adult-Onset Still’s Disease [2]A n e m i a [ 4]
Rheumatoid arthritis [5] Restless leg syndrome [6]
Macrophage activation syndrome [7] Neuroferritinopathy [8]
Multiple sclerosis [9] Vitamin C deﬁciency
Haemochromatosis [10–12] Celiac disease [13]
Haemosiderosis [10–12] Hypothyroidism [14]
Haemophagocytic lymphohistiocytosis
[15, 16]
Diabetes [17]
Hepatitis C infection [17, 18]
Glomerular diseases [19]
Hyperferritinemia cataract syndrome
[20]
Chronic blood transfusions [21]
Non-HIV infections [22]
Malignancies [22]
Type 1 Gaucher’s disease [23]
A study by Choi et al. on cytokines in AOSD showed
signiﬁcantly high IL-18, IFN-γ, and IL-8 levels in the sera
of AOSD patients than healthy controls. Also, soluble IL-2
receptors level was increased only in active stage of AOSD
which would indicate that soluble IL-2 receptor may be used
as a potential marker for monitoring the disease activity in
AOSD [42].
Cytokinesmayalsoaﬀectferritintranslationindirectlyby
theirabilitytoinducenitricoxidesynthase(iNOS)andhence
increase NO. NO in turn induces ferritin expression [53, 60].
The cytokine-mediated regulation suggests that inﬂam-
mation can aﬀect ferritin regulation.
There is also data to suggest that thyroid hormones play
ar o l ei nf e r r i t i ne x p r e s s i o n[ 53, 61].
Lipopolysaccharide (LPS; endotoxin), an outer mem-
brane component of several Gram-negative bacteria, elicits
a variety of reactions that involve ferritin [53].
In most studies, a threshold for serum ferritin levels
of 1000ng/mL, ﬁve times the upper limits of normal (40–
200ng/mL), has been used to suggest the presence of
AOSD [28]. Very high levels ranging from 4000ng/mL to
30,000ng/mL arenot uncommon, andevenextreme levels as
high as 250,000ng/mL have been reported [2]. Ferritin levels
inAOSDareusuallyhigherthanthosefoundinpatientswith
other autoimmune or inﬂammatory diseases [44]. It is not
clear yet whether ferritin plays a role in the disease patho-
genesis or it is just an acute phase reactant/silent bystander.
In patients with chronic hepatitis C, ferritin and AST levels
have been correlated, although increased ferritin does not
seem to have a role in the extrahepatic manifestations of
the disease. Also, in these patients, increased ferritin levels
are not associated with the B-cell dysfunction represented
by cryoglobulin and nonorgan-speciﬁc antibody production
[18]. Additionally, there are several diseases associated with
high ferritin levels that do not share any symptoms or signs
Table 2: Ferritin implicated in the pathogenesis of the following
diseases.
Atherosclerosis [29]
Diabetes [17]
Parkinson’s disease [30]
Alzheimer disease [31]
Pulmonary disease [32]
of AOSD. The usefulness of serum ferritin is limited by the
fact that elevated levels can also be seen in other diseases,
such as inﬁltrative diseases (hemochromatosis, Gaucher’s
disease), infections (sepsis, HIV), malignancies (leukemia,
lymphomas), and in the macrophage activation syndrome
[62]. Table 1 illustrates all the diseases where ferritin levels
increase or decrease, whereas Table 3 provides a summary
of the studies of autoimmune diseases where ferritin is in-
creased. Furthermore, there are several well-documented
reports of AOSD without increase in ferritin levels, hinting
on possible diﬀerent underlying mechanisms [37].
Interestingly, serum ferritin levels often correlate with
disease activity and can normalize when the disease goes into
remission [47, 49, 63]. Ferritin is known to release free Fe2+
ions, which catalyze the reaction leading to the formation
of free OH−1 radicals, although it can also chelate these free
Fe2+ ions, thereby limiting the deleterious eﬀects of oxidative
stress [64, 65]. The unresolved question is whether ferritin
acts as a buﬀer to minimize the pathogenic eﬀects of free
radicals or is it the one to cause the release of them.
3.5. Ferritin Glycosylation in AOSD. In healthy individuals,
50–80% of ferritin is glycosylated and the attachment of
glucose molecules at the surface of the ferritin molecule may
provide protection against proteolytic enzymes. There have
been several studies which point to the fact that AOSD
patients have low glycosylation levels (<20%) [37, 40]. Ab-
normally,lowlevelsofferritinglycosylationwereshowntobe
amorespeciﬁc,albeitlesssensitive,diagnostictestforAOSD.
Unfortunately, this test is not readily available in clinical
practice, hence limiting its usefulness. Moreover, ferritin
glucosylation remains low both during active state and in
remission, unlike serum ferritin levels [40]. The pathogenic
mechanisms underlying the decrease in glycosylation are
poorly deﬁned. A probably theory could be that, due to
excess of ferritin, the glycosylation process could be satu-
rated. In addition to saturation of glycosylation mechanisms,
abnormalities that are more speciﬁc of AOSD have been sug-
gested, particularly decreased clearance of nonglycosylated
proteins by the histiocyte-macrophage system.
The defect in ferritin glycosylation, although more spe-
ciﬁc for the diagnosis of AOSD than serum ferritin, is by
no means pathognomonic for the disease and has several
limitations. Individual patients can have normal levels of
glycosylationandlowglycosylationlevelscanbeseeninother
inﬂammatory disorders and in a few patients with infectious
diseases[37].Glycosylatedferritincannotbeusedtomonitor
disease activity or response to treatment, as it remains low4 International Journal of Inﬂammation
Table 3: Hyperferritinemia in Adult-Onset Still’s Disease patient cohorts (n ≥ 4).
Name Year Number of patients Results
Zandman-Goddard and
Shoenfeld [34] (Israel) 2008 403 autoimmune disease patients Hyperferritinemia in 23% SLE patients, 15% dermatomyositis,
8% multiple sclerosis, 4% rheumatoid arthritis
da Costa et al. [35] (Brazil) 2011 150 multiple sclerosis patients 8% of MS patients had hyperferritinemia
Lian et al. [36] (China) 2010 48 AOSD patients and 86
non-AOSD patients Signiﬁcantly higher levels of hyperferritenemia in AOSD
Fautrel et al. [37] (France) 2001 49 AOSD and 120 control group
patients
Mean ferritin level was signiﬁcantly higher in AOSD than in
control group
Sobieska et al. [38] (Poland,
Germany, Switzerland,
France)
1998 27 AOSD and 10 pediatric Still’s
Disease patients.
Mean ferritin level was signiﬁcantly higher in AOSD than
children
Schiller et al. [39] (Austria) 1998 4 AOSD patients All ferritin levels >5000ng/mL
Vignes et al. [40] (France) 2000 14 AOSD patients Mean ferritin level was 6350ng/mL
Uppal et al. [41] (Kuwait) 2007 28 AOSD patients Hyperferritinemia in 89% patients
Choi et al. [42] (Korea) 2003 17 AOSD patients Hyperferritinemia in 14 patients
A r l e te ta l .[ 43] (France) 2006 6 AOSD patients with
haemophagocytic syndrome Serum ferritin level above 10,000ng/mL in 5 patients
Coﬀernils et al. [44]
(Belgium) 1992 10 AOSD patients Hyperferritinemia in 8 patients
Ota et al. [45] (Japan) 1987 5 AOSD patients, 7 RA patients Mean ferritin levels in AOSD were 21,565ng/mL, whereas, in
RA, mean levels were 181ng/mL
Baxevanos et al. [46] (Greece) 2011 22 AOSD patients Hyperferritinemia in 21 patients
Akritidis et al. [47] (Greece) 1997 9 AOSD patients 8 patients had ferritin levels above 4000ng/mL
Montecucco et al. [48] (Italy) 1995 4 AOSD patients, 7 RA patients All 4 AOSD patients had hyperferritinemia and had mean
ferritin greater than RA patients
Van Reeth et al. [49] (France) 1994 20 AOSD patients Ferritin levels are higher in active AOSD than in inactive AOSD
for many months after the disease goes into remission [40].
Glycosylated ferritin (<20%) has a sensitivity of 78% and
speciﬁcity of 64%. When glycosylated ferritin levels are
combinedwithaﬁvefoldserumriseinferritin,thesensitivity
fell to 43% and speciﬁcity rose to 93% [37]. Therefore, the
combined use of both parameters has been suggested and
included in the Fautrel et al. criteria.
3.6. Ferritin Association with Atherosclerosis. AOSD is one of
the diseases under the banner of autoinﬂammatory diseases,
a new disease category where atherosclerosis has been sug-
gested as a possible member. Ferritin has also been impli-
cated in the pathogenesis a number of diseases (Table 2).
It has been described more clearly and signiﬁcantly in
atherosclerosis [17, 29, 66–68]. Epidemiological studies have
linked elevated serum ferritin levels with an increased risk
for coronary artery disease (CAD) and myocardial infarc-
tion (MI) [63]. This ﬁnding led to the “iron hypothesis”
which suggested a link between abnormal iron storage and
atherosclerosis. Furthermore, the hemochromatosis gene
(HFE), C282Y, has been associated with an increased risk
of CAD and cardiovascular mortality [69, 70]. There is
an ongoing debate whether ferritin acts as a prooxidant,
releasing free iron that was previously bound to it, or
antioxidant, sequestering excess unbound iron. Excessive
iron in tissues can catalyze the formation of oxygen-free
radicals that can lead to low-density lipoprotein (LDL)
oxidation, a trigger for the development of atherosclerosis.
3.7. Mutated Ferritin Theory. During infection or inﬂam-
mation, iron is sequestered in the ferritin contained inside
macrophages, and, as a result, serum iron decreases. This
artiﬁcial “iron deﬁciency,” which in reality is scarcity in the
midst of plenty, is thought to be protective for the host,
depriving invading microorganisms from much needed iron
[71]. Some research suggested that iron release is defective
due to the hyperferritinemia in AOSD [72, 73]. Reports
of iron supplementation successfully treating systemic-onset
juvenile chronic arthritis [74] prompted the performance of
iron studies on AOSD patients, showing iron deﬁciency, and
suggested that low-dose intravenous iron supplementation
could be eﬀective in AOSD patients with anemia [48, 74, 75].
The investigators suggested that intravenous iron could by-
pass macrophage trapping and become directly available for
erythropoiesis. This strategy could prove to be eﬀective in
anemic AOSD patients who often have normal or increased
iron stores. Despite the massive amounts of circulating
ferritin, its saturation with iron molecules since AOSD is not
associated with iron overload [40, 76, 77]. This has also been
proven with the use of automated analyzers that measure
the transferring receptors in the serum [78]. Moreover, since
the serum-transferring receptor concentration is not altered
in inﬂammatory states, it may be a more useful test than
serum ferritin in assessing the iron stores in AOSD [79]. The
defective release of iron from ferritin could be secondary to
the presence of a mutant form of ferritin, which could also
explain the defect in ferritin glucosylation seen in AOSD.International Journal of Inﬂammation 5
4. Conclusion
Very high and often extreme serum ferritin levels have been
described in AOSD for more than 2 decades now. While
widely thought to be an acute phase reactant, ferritin could
be intimately involved in the disease pathogenesis as an ox-
ygen radical donor or scavenger or via a yet to be deﬁned
mechanism, possibly including mutated ferritin. Further
research is warranted to bridge the knowledge gap and iden-
tify the missing links.
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